Myricetin treatment resulted in an increase of active GSK-3β by 245.6% (p < 0.01 vs. vehicle control) and 203.8% (p < 0.01 vs. vehicle control), in small intestinal and colonic polyps, respectively. Here, GSK3B is linked to polyp of colon.